# Efalizumab for Moderate to Severe Atopic Dermatitis

> **NCT00226057** · PHASE1 · COMPLETED · sponsor: **Oregon Health and Science University** · enrollment: 10 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** Raptiva

## Key facts

- **NCT ID:** NCT00226057
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2005-11
- **Final completion:** 2006-05
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00226057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00226057, "Efalizumab for Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00226057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*